Literature DB >> 3873214

Use of a time-kill technique for susceptibility testing of Trichomonas vaginalis.

J N Krieger, C S Dickins, M F Rein.   

Abstract

The emergence of metronidazole-resistant Trichomonas vaginalis and questions about the safety of metronidazole are significant concerns in treatment of trichomoniasis. At 24 h, a microtiter assay was used to test antimicrobial susceptibility of 16 recent isolates; the MICs of metronidazole ranged from less than 0.06 to 25 micrograms/ml. Observable motility as an endpoint correlated imperfectly with survival as measured in pour plates. Quantitative pour plate cultures of six T. vaginalis isolates after timed exposures to antimicrobial drugs demonstrated exquisite sensitivity to metronidazole with minimal trichomonacidal concentrations of 0.025 to 0.100 micrograms/ml. Killing of some T. vaginalis isolates by clotrimazole and rosoxacin occurred only at concentrations of 100 micrograms/ml. Resistance to both rosoxacin and clotrimazole correlated with increasing resistance to metronidazole (P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873214      PMCID: PMC176271          DOI: 10.1128/AAC.27.3.332

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Inactivation of metronidazole by aerobic organisms.

Authors:  D I Edwards; E J Thompson; J Tomusange; D Shanson
Journal:  J Antimicrob Chemother       Date:  1979-05       Impact factor: 5.790

2.  The treatment of trichomonas and candida vaginitis with clotrimazole vaginal tablets.

Authors:  H P Legal
Journal:  Postgrad Med J       Date:  1974-07       Impact factor: 2.401

3.  Studies on strain sensitivity of Trichomonas vaginalis to metronidazole.

Authors:  J G Meingassner; L Havelec; H Mieth
Journal:  Br J Vener Dis       Date:  1978-04

4.  Isolation of Trichomonas vaginalis resistant to metronidazole.

Authors:  J Thurner; J G Meingassner
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

5.  Assay conditions and the demonstration of nitroimidazole resistance in Tritrichomonas foetus.

Authors:  J G Meingassner; H Mieth; R Czok; D G Lindmark; M Müller
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

6.  Sensitivity of Trichomonas vaginalis to metronidazole, tinidazole, and nifuratel in vitro.

Authors:  B Korner; H K Jensen
Journal:  Br J Vener Dis       Date:  1976-12

7.  Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles.

Authors:  J G Meingassner; J Thurner
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

8.  Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles.

Authors:  D G Lindmark; M Müller
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

9.  Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice.

Authors:  M S Legator; T H Connor; M Stoeckel
Journal:  Science       Date:  1975-06-13       Impact factor: 47.728

10.  Metronidazole for vaginal trichomoniasis. Seven-day vs single-dose regimens.

Authors:  W D Hager; S T Brown; S J Kraus; G S Kleris; G J Perkins; M Henderson
Journal:  JAMA       Date:  1980-09-12       Impact factor: 56.272

View more
  3 in total

1.  In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents.

Authors:  S D Sears; J O'Hare
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

2.  Inhibition of Trichomonas vaginalis motility by monoclonal antibodies is associated with reduced adherence to HeLa cell monolayers.

Authors:  J N Krieger; B E Torian; J Hom; M R Tam
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

3.  Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis.

Authors:  D E Nix; R Tyrrell; M Müller
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.